// App-Quantinova.ai

OC 16.3 : Increased Rate and Risk Factors of Venous Thromboembolism (VTE) in Older Patients (pts) with Melanoma Receiving Chemotherapy and/or Immune Checkpoint Inhibitors (ICI): a SEER-Medicare Analysis

Researchers

Presenter

  • T. Sussman

Principal Investigators

  • A. Khorana

Medical Centers

  • Dana–Farber Cancer Institute, Harvard Medical School, Boston, MA, United States

  • Case Western Reserve University, Cleveland, Ohio, United States

  • Cleveland Clinic Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland, OH

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Oncology (ONC)

  • Pulmonary/Respiratory Diseases

  • Blood/haematological Diseases

Disease

  • Venous thrombosis

  • Deep vein thrombosis

  • Pulmonary embolism

  • Melanoma

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • Ipilimumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved